Drug intelligence / Profile preview

DSP-9632P

Development stage: Phase 1
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Transdermal

Overview

DSP-9632P is a small molecule drug developed by Sumitomo Pharma for the treatment of levodopa-induced dyskinesia in Parkinson's disease. It acts as a partial agonist at the serotonin 5-HT1A receptor, aiming to modulate serotonergic signaling and thereby reduce dyskinesias that occur as a side effect of long-term levodopa therapy. The drug has been evaluated in Phase 1 clinical trials, including studies assessing its pharmacodynamics, safety, and tolerability following transdermal administration in patients with Parkinson's disease experiencing levodopa-induced dyskinesia[1][3][4][5][7].

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on DSP-9632P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DSP-9632P.

Explore the full profile